Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bass Wins Review Of Ampyra Patents, Denied Enbrel

This article was originally published in Scrip

Executive Summary

Shares of Acorda Therapeutics Inc. tumbled 10.7% on March 11 after word came late in the day the Patent Trial and Appeal Board (PTAB) of the US Patent & Trademark Office agreed to review four of the firm's patents on its FDA-approved multiple sclerosis drug Ampyra (dalfampridine) in response to so-called inter partes review (IPR) petitions filed by hedge fund manager Kyle Bass through his Coalition for Affordable Drugs.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064725

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel